Millennium kept by Merrill at neutral

Millennium Pharmaceuticals Inc. was maintained by Merrill Lynch analyst Thomas McGahren at a neutral rating. Merrill said the announced restructuring of Millennium's arrangement with Schering Plough Corp. concerning Integrilin is a positive step toward reducing its cost structure and refocusing efforts toward its core strength of oncology, but there is a lack of clarity regarding profitability and growth. Millennium shares Monday slipped $0.09, or 0.91%, to close at $9.84 on volume of 11,580,803 shares versus the three-month running average of 7,003,720 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.